Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 839 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Coronavirus reports – Part 7: “I’m more concerned about the second... November 24, 2020 FDA Approves Crizotinib for ALK-positive Inflammatory Myofibroblastic Tumour July 25, 2022 COVID-19 Vaccines May Be Less Effective in Some People with Cancer May 26, 2021 Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... May 22, 2024 Load more HOT NEWS How My Navy Career Helped Shape My Positive Attitude During My... Teacher Reads To Students One Day After Having Brain Surgery Telehealth-Based Cancer Care Surged during COVID. Will It Continue? FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute...